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Abstract: Technology for high-throughout scanning of the human genome and its encoded proteins have rapidly developed 
to allow systematic analyses of human disease. Application of these technologies is becoming an increasingly effective 
approach for identifying the biological basis of genetically complex neurological diseases. This review will highlight 
signiﬁ  cant ﬁ  ndings resulting from the use of a multitude of genomic and proteomic technologies toward biomarker discovery 
in neurological disorders. Though substantial discoveries have been made, there is clearly signiﬁ  cant promise and potential 
remaining to be fully realized through increasing use of and further development of -omic technologies.
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Introduction
The ultimate goals for research focused on complex human diseases are to either prevent or to cure the 
diseases. These are ambitious goals that will be greatly facilitated by the identification of new biomark-
ers that can serve as novel diagnostic or prognostic indicators of disease course, that can be used as 
surrogate disease markers to track the efficacy of novel treatment strategies, or that may provide new 
targets for the treatment of the diseases.
Neurological disorders present multiple unique challenges to biomarker discovery that are more 
extensively reviewed elsewhere (Dunckley et al. 2005). Briefly, the essential and vital role that the brain 
and central nervous system play in all aspects of life ensures the lack of availability of tissue at the site 
of pathology for most neurological disorders. Additionally, the ante mortem clinical diagnostics, although 
continually improving in most neurological diseases, remains problematic. In many diseases, such as 
Alzheimer’s disease and Parkinson’s disease, definitive diagnosis occurs only at autopsy with sometimes 
as many as 20% of cases being found to have been clinically misdiagnosed. Reliable genetic or protein 
based biomarkers specific for these diseases would clearly be useful for earlier and more accurate 
diagnoses and treatment interventions. Lastly, there are few animal models fully representative of the 
diseases that can be used for validation of candidate biomarkers. This is likely due in part to the increased 
complexity of the human brain, of human behavior, and the possibility that neurological diseases, many 
of which develop later in life and require an aging component, are difficult to recapitulate in shorter 
lived animals.
High-throughput technologies for studies of the human genome and proteome are advancing at a 
rapid pace and are increasingly being applied toward the study of neurological diseases to help overcome 
some of these hurdles. This review will focus on the application of these current high-throughput strat-
egies to biomarker discovery in neurological disease.
Genomics
The study of genomes, referred to as ‘genomics,’ has made substantial progress toward our understand-
ing of human disease and promises to direct the future of medicine toward more personalized diagnostics 
and therapeutics based on an individual’s specific genetic variations and predispositions to disease. The 
majority of complex human diseases have a genetic component that has historically been difficult to 
uncover using traditional genetic methods. Indeed there are numerous examples of the use of genomic 74
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technologies to identify novel biomarkers for mul-
tiple neurological diseases, including Alzheimer’s 
disease, Parkinson’s disease, Autism and Hunting-
ton’s disease among others (Borovecki et al. 2005; 
Coon et al. 2007; Dunckley et al. 2005 and 2007; 
Fung et al. 2006; International Multiple Sclerosis 
Genetics Consortium et al. 2007; Lee et al. 2007; 
Maraganore et al. 2005; Papapetropoulos et al. 
2007; Papasssotiropoulos et al. 2006; Reiman et al. 
2007; Scherzer et al. 2007; Schymick et al. 2007; 
Tang et al. 2005; Ulmann et al. 2007; van Es et al. 
2007). However, critical findings that have been 
translatable to clinical application seem to be 
intermittent at best due to the challenges facing 
neurological research as previously discussed.
The genetic underpinnings of mendelian forms 
of disease have been pieced together using famil-
ial genetic approaches, such as linkage studies, 
where whole families are studied to find commonly 
inherited mutations associated with disease. This 
approach has been successful in identifying the 
genetic causes of some very prominent familial 
forms of neurodegenerative diseases, such as 
Alzheimer’s disease (AD) and Parkinson’s disease 
(PD). However, even with these common disor-
ders, familial cases account for a small fraction of 
individuals afflicted with the disease. A significant 
challenge lay both in developing biomarkers for 
and understanding the causes of the much more 
prevalent sporadic forms of complex neurological 
diseases, such as late onset AD (LOAD). In the 
following sections, the main genomic technologies 
currently being applied to this problem will be 
described and recent findings discussed. These 
areas include array CGH (array comparative 
genomic hybridization), gene expression profiling, 
whole genome association studies using single 
nucleotide polymorphisms (SNPs), and, more 
toward the future, whole genome resequencing to 
identify causal disease-associated DNA sequence 
variants.
Array CGH
On a functional level, array comparative genomic 
hybridization (aCGH) measures copy-number 
variations at multiple locations in the genome 
simultaneously (Barrett et al. 2004) by comparing 
DNA content from two differentially labeled 
genomes: one being the patient (or test) genome 
and the second being the control (or reference) 
genome (Bejjani and Shaffer, 2006). Both genomes 
are isolated, fluorescently tagged with different 
fluors, and then competitively hybridized to a solid 
surface where cloned or synthesized DNA frag-
ments corresponding to defined segments of 
genomic DNA have been bound (Bejjani and 
Shaffer, 2006). Once an image of the slide has been 
captured, the level of fluorescence signals from 
each DNA sample for each target placed on the 
array is calculated (Bejjani and Shaffer, 2006). The 
relative fluorescence intensity of the test genome 
compared to the reference genome provides a 
measure of the number of DNA copies in that 
region of the genome in disease versus control. 
Using this technology one can show changes such 
as deletions, duplications, or amplifications at any 
locus that is represented on the array (Bejjani and 
Shaffer, 2006). Unlike FISH (fluorescence in situ 
hybridization), which is limited in the number of 
loci that can be simultaneously interrogated, aCGH 
is able to detect DNA copy number changes at 
hundreds of thousands of loci in a genome in a 
single experiment and thus provides a far more 
rapid and facile method for detecting genomic copy 
number variations associated with disease.
Originally developed as a research tool to iden-
tify copy number variations in cancer (Barrett et al. 
2004; Bejjani and Shaffer, 2006), aCGH is one area 
that is still in its beginnings with respect to appli-
cations in neurological research. It is typically used 
for discovering disease-associated loci and devel-
oping diagnostic or therapeutic targets in cancer 
and developmental disorders (Barrett et al. 2004). 
Only a small number of studies have recently 
explored the application of aCGH to the study of 
neurological disease. These efforts have focused 
primarily on mental retardation, autism and various 
forms of epilepsy (Bonaglia et al. 2005; Ulmann 
et al. 2007; Toruner et al. 2007; Edelmann et al. 
2007). Neurodegenerative diseases specifically 
have yet to be researched. This may be due in part 
to the lack of high quality tissue samples from 
affected disease areas, a key element for reliable 
aCGH results. Additionally, with the notable 
exception of α-synuclein locus triplication in a 
familial form of Parkinson’s disease (Singleton 
et al. 2003), there is not much evidence to suggest 
that structural genomic abnormalities or changes 
in copy number broadly underly neurodegenerative 
diseases. This may however simply reflect a lack 
of sufficient investigation in this area. However, 
as tissue collection methods are improved and 
standardized, aCGH technology may yet reveal 75
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additional significant alterations associated with 
neurological disease.
Array CGH has been suggested as a potential 
diagnostic tool to personalize treatment strategies. 
Recently, aCGH has been used to detect copy num-
ber alterations in the PLP1 region for prenatal diag-
nosis of Pelizaeus-Merzbacher disease (PMD) (Lee 
et al. 2005), a rare X-linked dysmyelinating disorder 
of the central nervous system (Garbern et al. 1999; 
Inoue, 2005). Genomic duplications of the PLP1 
(proteolipid protein 1) gene is one of the main causes 
of PMD, and has been used to molecularly diagnose 
the disease by interphase FISH and quantitative 
multiplex PCR methods using blood samples in 
children and adults (Lee et al. 2005; Inoue et al. 
1996). It is also well established in prenatal diagno-
sis by using either amniotic fluid or chorionic villus 
sampling (Lee et al. 2005; Woodward et al. 1999; 
Inoue et al. 2001; Regis et al. 2001). Array CGH has 
been used to successfully detect PLP1 copy number 
in the developing fetus and provides the noted ben-
efit of being more efficient than one FISH experi-
ment (Lee et al. 2005). The specific size of genomic 
duplication can also be determined using aCGH 
provided that the probe density is sufficient, some-
thing that is more labor intensive using FISH. One 
limitation of aCGH however is that it cannot detect 
other rearrangements, such as inversions or balanced 
translocations. Nevertheless, aCGH provides a rapid 
diagnostic for PMD and establishes the utility of this 
technology for assisting in the diagnosis of neurologic 
diseases.
This paradigm of using aCGH as a diagnostic 
tool may yet prove useful in other neurological 
diseases as emerging evidence is beginning to link 
copy number alterations to complex neurological 
disorders. For example, Ulmann et al. recently 
identified reciprocal duplications and deletions on 
chromosome 16p13.1 that are associated with 
autism and/or mental retardation (MR) (Ulmann 
et al. 2007). With further validation of this genetic 
association, aCGH may provide a more accurate 
diagnostic tool for a subset of autistic individuals. 
This is particularly important in autism where the 
difficulty in making a definitive clinical diagnosis 
often delays administration of appropriate behav-
ioral therapy, which is substantially more effective 
when initiated early in life.
It should be noted that changes in copy number 
are remarkably common in the human population, 
irrespective of association with disease (Bejjani 
and Shafer, 2006). Therefore to identify a copy 
number change that is sensitive and specific for a 
complex neurological disease, such as autism or 
Alzheimer’s disease, will likely require the initial 
study of thousands of patients and controls to 
derive sufficient power to detect a consistent and 
significant association with disease, if such an 
association exists.
Gene expression proﬁ  ling
Gene expression microarrays are used to rapidly 
assess the expression of thousands of genes in a 
single experiment, generating specific “expression 
profiles” of normal and disease states. There are 
two basic types of microarrays commonly used 
(Schena et al. 1995; Shalon et al. 1996; DeRisi 
et al. 1996). Both fix DNA probes to a solid sur-
face. However, one type of array uses cDNA for 
probes (usually 200–2000 nucleotides long) and 
another uses oligonucleotides (usually 25–70 
nucleotides long). Labeled cRNA (or cDNA) is 
then hybridized to the array and binds to specific 
regions of the array that contain probes of comple-
mentary sequence. Expression levels are calcu-
lated based on the quantity of signal coming from 
each probe location, which is related to the amount 
of labeled cRNA or cDNA bound to the array at 
that location. Oligonucleotide arrays have greater 
specificity, as well as the ability to distinguish 
between splice variants if probe sets are designed 
to cover different exons, as is the case specifically 
for exon arrays. Although cDNA arrays have 
higher sensitivity resulting from the increased 
probe length, they often cannot be designed to 
distinguish between splice variants because the 
length of the DNA probes usually span splice 
junctions.
A typical experiment will compare tissue from 
a healthy control to tissue from an individual 
affected by a specific disease. The mRNA is iso-
lated, amplified, converted to cDNA, and labeled. 
Samples are then hybridized to the probes on the 
arrays, which correspond to regions of specific 
genes of interest, and imaged. Comparison of the 
expression profile for the healthy tissue to that from 
the disease tissue will identify specific gene dys-
regulation correlated with the disease of interest. 
This disease related expression signature provides 
information about the underlying cellular dysfunc-
tion involved in disease pathogenesis, or could be 
used as a diagnostic gene expression signature to 
help guide treatment options.76
Robeson et al
Biomarker Insights 2008:3 
Given the large number of genes interrogated 
in each experiment, reproducibility is a key issue. 
Multiple reports have addressed this issue and 
results show that intra-platform reproducibility is 
significantly higher than inter-platform reproduc-
ibility (Hollingshead et al. 2005; Shi et al. 2006; 
Canales et al. 2006). This likely results from the 
fact that different manufacturers use unique sets 
of probe sequences, each with different hybridiza-
tion efficiencies. Thus for the most consistent 
results, repeated measures should use the same 
platform for all comparisons. For identifying 
validated correlates of disease that are indicative 
of the underlying disease-relevant mechanisms, 
typically 15 to 20 case samples and 15 to 20 con-
trol samples are needed (MacDonald et al. 2001; 
Dunckley et al. 2006). However, due to disease 
heterogeneity, varied environmental influences and 
inter-individual variability, development of spe-
cific and sensitive diagnostic expression signatures 
requires a larger number of samples, typically from 
30 to 100 or more cases and controls (Shirahata 
et al. 2007; Magic et al. 2007; see also Burcszynski 
et al. 2005 and references therein). Of course, more 
samples will increase the likelihood of generating 
more specific and sensitive expression signatures 
diagnostic of disease.
Gene expression profiling has been very useful 
for identifying the underlying cellular changes 
involved in idiopathic and multifactorial diseases, 
including neurodegenerative disorders such as AD 
and PD (Papapetropoulos et al. 2007). One of the 
advantages of gene expression profiling is its 
applicability to any tissue sample that contains 
intact mRNA, such as brain tissue or blood. Impor-
tantly, identification of disease-specific differences 
in gene expression in blood would provide a facile 
diagnostic biomarker for neurological disease, 
although thus far no such reliable biomarker has 
been forthcoming.
Currently there is a large amount of ongoing 
research using gene expression profiling in neuro-
logical diseases. However, the context of biomark-
ers seems to have the most clinical potential when 
looking primarily at blood samples. Recently, 
Sharp et al. identified sensitive genomic profiles 
for human individuals who suffered an ischemic 
stroke that were also specific for predicting strokes 
(Sharp et al. 2006). In a previous study, this group 
also looked at individuals with Down syndrome 
and found that they could see different expression 
profiles in the blood that reflected different phe-
notypes appearing within the disease (Tang et al. 
2004). Multiple differentially expressed genes have 
also been identified in natural killer and CD8 cells 
of individuals with Tourette syndrome (TS) (Tang 
et al. 2005; Sharp et al. 2006).
Another recent study looked at potential diag-
nostic gene expression markers for Parkinson’s 
disease (PD) in blood (Scherzer et al. 2007). Using 
a two-stage experimental design with a training 
and validation population, a set of dysregulated 
genes was significantly associated with risk of PD 
(odds ratio = 5.7). The set of genes identified pre-
dict PD significantly more effectively than current 
prediction methods, which include the risk factors 
of age and sex (Scherzer et al. 2007). The genes 
within this set do not correlate to a single pathway, 
but all are known to be expressed in the human 
brain (Rebhan et al. 1998; Kalchman et al. 1996). 
Also, many of the genes seem to be previously 
identified or associated with PD or with a major 
process that could be contributing to PD. With no 
current laboratory test available and early detection 
of PD being clinically difficult, these findings may 
advance the development of diagnostic biomarkers 
for PD. Furthermore, it is striking that dysregulated 
genes identified in peripheral blood samples in this 
study reflect many of the known pathogenic 
mechanisms occurring in the brain of patients with 
PD. This suggests that in some cases insights into 
biological pathogenesis of neurological diseases 
may be gained from identifying aberrations in 
blood samples, despite the presence of an intact 
blood-brain barrier.
Another interesting study examined gene 
expression profiles in a group of patients suffering 
from Huntington’s disease (HD) (Borovecki et al. 
2005). These authors identified a subset of mRNAs 
that successfully distinguished controls from pre-
symptomatic individuals with the HD mutation and 
from symptomatic HD patients (Borovecki et al. 
2005). Thus, these dysregulated genes were able 
to discriminate the different stages of the disease, 
suggesting that this marker set is able to monitor 
disease progression. In addition, numerous genes 
from this biomarker set were also dysregulated in 
HD post-mortem frozen brain samples. Thus, this 
example and the one above for PD suggest that 
dysregulation in blood may reflect dysregulation 
occurring in the brain during the course of neuro-
degenerative diseases. For HD, the correlation 
between brain and blood may mechanistically 
result from mutated huntingtin protein similarly 77
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affecting brain and blood targets. These provide 
useful examples of the study of peripheral tissues 
to gain insights into the pathology occurring in a 
less accessible, but more functionally relevant tis-
sue, the brain.
The findings from these studies and many others 
illustrate the potential and evolving capability of 
gene expression profiling to determine distinct 
profiles attributed to different phenotypes in a 
disease, to identify individual subtypes of complex 
diseases like Tourette Syndrome, autism and 
others that possibly have central environmental 
and genetic factors contributing to the disease 
(Sharp et al. 2006), and also to develop a way to 
monitor disease progression, early recognition and 
correlate activities in the brain to markers in 
blood.
Single nucleotide polymorphisms
Any two humans are 99.9% identical at the DNA 
sequence level. However, it is the 0.1%, or ~1 
nucleotide in 1,000, variation that defines our 
uniqueness as well as our differential susceptibility 
to diseases. Single Nucleotide Polymorphisms 
(SNPs) represent single base pair differences 
between individuals at a specific location in the 
genome. There are an estimated 10 million SNPs 
that differ between individuals in the population 
(Ardlie et al. 2002; Carlson et al. 2003; Kruglyak 
and Nickerson, 2001). A comprehensive catalogu-
ing effort of these variable positions through mul-
tiple efforts, including the SNP consortium (TSC), 
the Celera sequencing effort, and the HapMap 
project now allows the utilization of these SNPs 
to interrogate the specific combinations of SNPs 
that, when co-inherited, predispose to any human 
trait. Only recently have genomic advances 
matured to the point that genotyping large numbers 
of SNPs to address the genetics of complex disease 
is becoming possible.
SNPs are grouped into three functional classes. 
The first group contains the classically defined 
Mendelian inherited single base-pair mutations. 
These are single SNPs occurring in the coding 
region of genes that alter the protein sequence of 
the gene product or that result in premature trunca-
tion of the encoded protein. These are predicted to 
have strong functional effects on their own. The 
second class of SNPs, referred to as functional 
SNPs, consist of those that have subtle effects on 
gene function or expression, contributing to disease 
only when occurring in the context of additional 
genetic variants or environmental influences. The 
third category consists of nonfunctional SNPs, 
those that are functionally completely silent, but 
may nevertheless be of interest due to genetic link-
age to a nearby functional DNA sequence variant. 
The majority of SNPs fall into this category.
Functional SNPs are of particular interest in the 
study of common and complex neurological dis-
orders since they are thought to occur at high 
frequencies in the general population and to result 
in disease when occurring in specific combinations. 
Recent advances in high-throughput SNP genotyp-
ing technologies provide an opportunity to identify 
these SNPs in large case-control association stud-
ies of complex neurological diseases. SNP analysis 
also enables more rapid identification of Mendelian 
inherited diseases through linkage analyses, in 
some cases Condensing The previous time-frame 
for disease gene identification from several years 
for traditional approaches to less than a week for 
high-throughput SNP based assays (Puffenberger 
et al. 2004). Here we discuss applications to com-
plex neurological disorders as this class comprises 
the majority of neurological disease.
Analyzing Complex, Multigenic 
Disorders
SNP genotyping technology holds great potential 
for discovering multigenic contributions to com-
plex neurological disorders. These disorders are 
usually not inherited in a Mendelian fashion and, 
in many cases, may be referred to as “sporadic” 
cases of disease, which are ideally studied using 
case-control whole genome association studies of 
outbred populations.
The development of SNP scanning technology 
now allows the simultaneous testing of more than 
a million genetic variants, enabling initial studies 
into the genetics of complex disorders. Specific 
issues related to the technology of SNP association 
studies, including sample size, SNP density, and 
data analysis methods, are reviewed more extensively 
elsewhere (Craig and Stephan, 2005; Dunckley et al. 
2006a). Here we will discuss how the technology 
has been applied to neurological disorders and 
significant findings that have resulted.
Numerous neurological disorders have been 
examined using high-density, whole genome SNP 
association studies. These include Alzheimer’s 
disease (Coon et al. 2007; Reiman et al. 2007), 78
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Parkinson’s disease (Fung et al. 2006; Maraganore 
et al. 2005), multiple sclerosis (International 
Multiple Sclerosis Genetics Consortium et al. 
2007), amyotophic lateral sclerosis (Dunckley 
et al. 2007; van Es et al. 2007; Schymick et al. 
2007), bipolar disorder (Wellcome Trust Case 
Control Consortium, 2007; The GAIN Collaborative 
Research Group et al. 2007; Baum et al. 2007), 
and ischaemic stroke (Matarin et al. 2007).
In the majority of these diseases, it is striking 
that there are no single allele variants that account 
for the bulk of disease risk. The notable exception 
is that of Alzheimer’s disease, where whole 
genome SNP association studies confirm that the 
apolipoprotein E (ApoE) locus confers the largest 
genetic susceptibility to AD. However, when indi-
viduals are grouped and analyzed according to their 
ApoE genotypes, multiple SNPs within the GRB2 
associated protein 2 (GAB2) gene have been 
reported to be significantly associated with AD risk 
in carriers of the ε4 allele of APOE (Reiman et al. 
2007). These findings await further confirmation. 
However, this study provides a glimpse into what 
SNP based genotyping technology offers for the 
future in terms of uncovering interactions between 
multiple genetic loci that lead to an aggregate 
genetic risk for disease.
Association studies in other diseases usually 
identify few loci with high odds ratios (ORs) for 
disease. In this regard, Alzheimer’s disease is now 
clearly an exception among complex human 
diseases. The typical result appears to be identification 
of multiple loci with ORs less than 2. For example, 
a recent study in amyotrophic lateral sclerosis 
identified a dozen loci reproducibly associated with 
disease (Dunckley et al. 2007). However, no locus 
exceeded a 2-fold OR. Importantly, the multiple loci 
that were identified highlight distinct functional 
categories of genes. The most prominent among 
these groups are genes involved in neurite outgrowth. 
For example, a SNP within the anaplastic lymphoma 
kinase gene (ALK) was associated with ALS with 
an OR of 1.57. Independent studies showed that 
ALK is critical for pleiotrophin-mediated axonal 
regeneration in spinal motor neurons and is 
necessary for neuroprotection in response to 
glutamate excitotoxicity (Mi et al. 2007). These 
observations, coupled with genetic association to 
sporadic ALS, suggest that variations in the ALK 
gene could have subtle functional consequences that 
alter the axonal dynamics of motor neurons, 
ultimately leading to the development of ALS.
This study in ALS also identified candidate 
SNPs associated with clinical subclasses of ALS 
that differ in site of symptom onset, age at onset, 
and gender-based differences in disease onset. With 
further validation and confirmation, these SNPs 
could provide the basis for presymptomatic risk 
assessment to determine individuals at risk for not 
only developing ALS, but also for developing 
specific forms of ALS. This information could then 
be used to direct differentially treatment options. 
Importantly, this type of analysis highlights the 
direction that SNP based diagnostics and risk 
assessment strategies are headed to impact disease 
treatment approaches before initial symptoms 
occur. This may be a particularly important 
approach in neurodegenerative diseases where 
substantial neuronal cell loss and pathology has 
already occurred by the time a clinical diagnosis 
is made. Treatments are likely to be more effective 
prior to this advanced cell loss.
The use of SNP association studies for identify-
ing multigenic contributions to complex disease 
risk is clearly in the early stages. The relatively 
low risk contributed by individual alleles will 
necessitate the study and analysis of significantly 
larger patient populations than have currently been 
studied. Identification of consistently reproducible 
genetic variants associated with complex human 
disease is likely to require tens of thousands of 
samples. Indeed, large initiatives such as the Well-
come Trust Case Control Consortium and the 
GAIN collaborative research initiative are making 
the first important steps toward the study of these 
larger populations. However, these efforts must be 
expanded upon.
The utility of identifying genetic variants for 
complex diseases lies in their use as a predictor of 
disease risk, as a diagnostic for disease, as a predic-
tor of response to therapy, or for the identification 
of therapeutic targets. For example, currently 
genetic testing is done one gene at a time using a 
candidate gene approach. That is, one has a family 
history of a particular disease for which a common 
genetic variant is known, such as cystic fibrosis, 
and can be tested for the presence of that variant 
within their genome. This information can then be 
used to guide life decisions, such as reproductive 
choices or exercise and eating habits in instances 
of other disorders. However, most human disease 
is sporadic and multigenic. Risk for these diseases 
cannot be diagnosed using traditional approaches. 
SNP analysis can be performed on a genome-wide 79
Genomic and proteomic biomarker discovery in neurological disease
Biomarker Insights 2008:3 
scale in large case-control association studies of 
outbred populations to identify all of the genetic 
variants that contribute simultaneously to a specific 
disease. These variants can then be packaged into 
a prognostic test to predict an individual’s overall 
genetic risk for developing a given disease. These 
prognostic tests would be most effective when 
coupled to an effective therapeutic or prevention 
strategy. However, such a test to assess disease risk 
could have a significant impact on human health, 
even in the absence of a specific therapy because 
environmental influences, which are modifiable, 
also affect the development and course of disease. 
For example, high cholesterol diets or smoking 
have been shown to increase the risk of some forms 
of cancer and may also be an important factor in 
the development of Alzheimer’s disease. Knowing 
that you are at heightened genetic risk for these 
disorders could motivate significant lifestyle 
changes. In this way, as the analysis of complex 
diseases continues to evolve, the ease of use and 
the versatility of SNP genotyping for identifying 
relevant genetic variants, such as point mutations, 
deletions, and insertions, will lead to significant 
advances in human health.
Summary
Figure 1 provides a flow diagram illustrating the 
interconnected components of the various genomic 
technologies for the identification of neurological 
disease biomarkers. These biomarkers can be used 
as diagnostics or, potentially, as therapeutic targets 
around which treatments could be directed. 
Importantly, these are complementary technologies, 
each providing unique information about the 
genetic and molecular factors contributing to the 
disease. However, these technologies though 
overlapping in their utility also have unique uses. 
For example, SNP-based screening, and to a lesser 
extent aCGH, are the likely the preferred options 
when trying to identify biomarkers that can be used 
in presymptomatic risk assessment. In contrast, 
gene expression profiling will only show differences 
when some component of the disease has already 
manifest itself and is functionally altering the 
physiology of the cells or tissues. As such, gene 
expression profiling can provide unique diagnostic 
signatures or can be used to identify underlying 
molecular changes associated with disease. These 
molecular factors may serve as targets for 
therapeutic development. A comprehensive 
genomic biomarker discovery strategy will utilize 
each of these technologies.
Proteomics
Proteomics refers to the systematic study of the 
expression, structure, and function of the proteins 
within cells. Ever improving technologies now 
permit the simultaneous detection and quantitation 
of several thousand proteins in normal and disease 
tissues and approaches for identifying post-
translational variants are beginning to come to the 
fore. For an extensive technological review of 
proteomics, the reader is directed to several 
excellent recent review articles (Tannu and 
Hemby, 2006; Butterfield et al. 2006; Andrade 
et al. 2007). The goal of this review is to highlight 
important findings that demonstrate the techno-
logical potential that proteomics holds for the 
discovery of biomarkers and therapeutic targets 
in neurological disorders. Brief technological 
descriptions will be given where appropriate. 
Advances in the application of genomics to bio-
marker identification have led to important 
insights into the pathogenesis of neurological 
diseases, as previously described. However, 
genomic analysis alone will not suffice as a 
method to fully characterize neurological disease. 
Expression of messenger RNA and the encoded 
protein are not universally correlated. Differences 
in stability and turnover between mRNA and pro-
tein contribute to this weak gene-protein associa-
tion. Additionally, proteins contain numerous 
post-translational modifications of high functional 
significance that cannot be inferred from mRNA 
expression. The proteins themselves must be ana-
lyzed directly (Rohlff, 2000). Thus, accurate 
monitoring of disease onset and progression 
requires current proteomic technologies for care-
ful detection of protein signatures and post-
translational modifications, in addition to the 
aforementioned genomic approaches to biomarker 
discovery.
Proteomics is an invaluable instrument in the 
search for novel disease biomarkers because cur-
rent technology provides the means to describe the 
expression of thousands of proteins in whole cell 
or biofluid samples (Kinoshita et al. 2006). Pro-
teomic analysis consists of two general steps: (1) 
fractionation of the complex protein mixture and 
(2) identification and quantitation of the separated 
proteins. Fractionation is usually accomplished 80
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using 2-dimensional (2-D) gel electrophoresis, 
liquid chromatography (LC), or both 
(Papasssotiropoulos et al. 2006). Proteins within 
the simplified mixture are typically identified using 
a mass spectrometry (MS) based approach, such 
as matrix assisted laser desorption/ionization 
(MALDI)-time of flight (TOF) MS or MALDI-
quadrupole TOF-tandem MS (MS-MS).
Two dimensional gel electrophoresis is the most 
widely used separation method. The 2-D descriptor 
refers to the two separation steps (dimensions) 
involved: separation of the proteins based on 
isoelectric point followed by separation based on 
protein molecular weight. In the first dimension, 
the protein mixture is applied to a polyacrylamide 
gel with a pH-gradient and an electric potential. 
Proteins then accumulate at their isoelectric point. 
In the second dimension, the gel containing the 
protein spots separated by charge are denatured 
with sodium dodecyl sulfate (SDS) and rotated 90 
degrees. An electric potential is again applied and 
the proteins move through the gel at a rate 
proportional to their sizes. Generally, 1000–3000 
proteins can be visualized per gel (Banks et al. 
2000). The resolved spots are then excised from the 
gel and proteolytically cleaved to smaller peptide 
fragments so that protein identification can proceed 
using mass spectrometry (MS) (Kinoshita et al. 
2006). This approach presents several limitations. 
First, it is difficult to get consistent results between 
different polyacrylamide gels. Differential two-
dimensional fluorescence gel electrophoresis 
(DIGE) can be used to overcome this variability. 
In this technique, protein samples from both a 
control sample and a test sample are fluorescently 
labeled with Cy3 and Cy5 and run simultaneously 
on the same gel. The fluorescence intensities can 
then be measured to calculate relative protein 
expression in control and test samples for each spot. 
Due to differences in dye incorporation efficiencies, 
Figure 1. Work ﬂ  ow for genomic biomarker discovery in neurological diseases. Outlined are approaches using both DNA-based and 
RNA-based technologies. Ultimately these are discovery approaches that then must be translated into clinical application through 
subsequent validation efforts and conﬁ  rmatory clinical trials.
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both test sample and control sample must 
alternatively be analyzed with both Cy3 and Cy5 
dyes (reciprocal labeling). Second, many proteins 
that are acidic or basic, hydrophobic, or of very 
high (200 kD) or low (10 kD) molecular mass, 
are not conducive to separation by 2-D gel 
electrophoresis and are more suited to separation 
via liquid chromatography (LC) approaches 
(Papasssotiropoulos et al. 2006). In LC, the protein 
mixture is typically first fractionated by one or a 
combination of binding interactions. Then the 
collected fractions are separated by reverse-phase 
high-performance LC prior to MS analysis 
(Papasssotiropoulos et al. 2006).
The most common method for protein identifi-
cation is matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-
MS). From analysis of a single tissue section, over 
1000 different proteins can be simultaneously 
examined. A critical issue in neurological diseases 
is the cellular complexity of the brain. One may 
first reduce this complexity by isolating a more 
homogeneous cellular population of interest 
(Kinoshita et al. 2006). To this end, single cells or 
a small, relatively homogenous region of tissue are 
isolated from a heterogeneous tissue sample using 
laser capture microdissection (LCM) before MS 
analysis. However, this approach adds substantial 
time and effort because the detection sensitivity of 
current proteomic technologies requires several 
hundred thousand cells as starting material for 
protein isolations. This is a particularly relevant 
limitation in neurological diseases since many 
functionally and disease relevant processes likely 
occur at synapses, where proteins may be less 
abundant and not necessarily reflected in the cell 
body collected in the LCM process. It is clear that 
advances in sensitivity of detection thresholds and 
in the ability to produce homogenous sample 
populations are required for full utility of pro-
teomics in understanding neurological disease.
Identification of specific proteins via MALDI-
TOF-MS follows these general processes. Selected 
molecules are desorbed from a protein sample that 
has been coated with an energy-absorbing matrix 
whereby they become protonated and usually carry 
one positive charge. These desorbed ions are accel-
erated by a potential difference through a flight 
tube to strike the ion detector at the end of the tube. 
Due to the fact that the energy of each cation is the 
same, acceleration is proportional to ion mass. Data 
is constructed as ion density maps by plotting 
mass/charge signal intensities over the sample area 
analyzed (Johnson et al. 2006). Overall, this 
method allows for high-throughput quantification 
of global protein expression in thin, heterogeneous 
tissue samples and is therefore an efficient tool in 
the search for neurological disease biomarkers.
Proteomic biomarker identiﬁ  cation 
in neurological diseases
Several studies have utilized proteomics to discover 
candidate biomarkers for Alzheimer’s Disease (AD). 
In one study, proteins enriched in amyloid plaques 
in the AD brain were separated and identified using 
liquid chromatography and mass spectrometry, 
respectively. Levels of about 100 proteins were 
found to differ in the AD brain and Cerebral Spinal 
Fluid (CSF) with respect to the control brain and 
CSF, with the biggest changes seen in the glial fibril-
lary acidic protein (GFAP) (Liao et al. 2004). GFAP 
is an intermediate filament protein that helps to 
maintain the shape and mechanical strength of 
astrocytes. Activation of GFAP correlates well with 
astrocyte activation (Fuchs and Weber, 1994). Lev-
els of this protein in AD affected individuals were 
observed to be 10-fold higher than in the control 
group, indicating significant astrocytic activation 
and active inflammatory processes in the AD brain. 
These results correlate very well with current knowl-
edge of pathogenic mechanisms in AD and other 
neurodegenerative disorders, wherein inflammatory 
processes are thought to be an important contributor 
to disease progression (Liedtke et al. 1996).
Decreased levels of copper-zinc superoxide 
dismutase (SOD1) have also been found in AD 
brain samples (Gulesserian et al. 2001). SOD1 is 
an antioxidant that catalyzes the simultaneous 
oxidation and reduction of superoxide anion into 
hydrogen peroxide. The altered response to oxida-
tive stress that would result from decreased SOD1 
activity may contribute to neuronal cell loss in AD, 
a common mechanism contributing to the patho-
genesis of many neurodegenerative diseases 
(Papasssotiropoulos et al. 2006).
The above two studies are reflective of others 
performed in the field in that they have not thus 
far yielded either significant new insights into the 
causes of AD or generated a reliable set of biomark-
ers that would be useful in the diagnosis of AD. 
Rather they have been useful for identifying pro-
teins involved in pathways that have already been 
implicated in the disease. The overall goal is that 82
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these and future efforts at proteomics of disease-
affected tissues will identify new targets for thera-
pies that may ultimately lead to effective treatments. 
However, technological and technical advances 
will need to be made to reduce both biological and 
technical variability to increase the likelihood of 
identifying consistent changes associated with 
disease. Additionally, the number of proteins, as 
well as the associated post-translational modifica-
tions, that can be identified and quantified will 
need to be increased substantially. A recent study 
has provided an indication of the promise of pro-
teomic technologies for biomarker identification 
and disease tracking and diagnosis. Lee et al. used 
sandwich ELISAs to identify a set of 18 proteins 
(from a preselected subset of 120 known signaling 
proteins) expressed in blood that distinguish 
Alzheimer’s disease patients from controls with 
almost 90% accuracy (Lee et al. 2007). Moreover, 
they were able to use this set of proteins to predict 
which patients with mild cognitive impairment 
(MCI), an early stage of cognitive impairment with 
high probability of progressing to AD, would 
advance to develop Alzheimer’s disease.
Levels of Aβ42 and total tau have shown a 
marked difference in AD patients (Blennow et al. 
2003; Andreasen et al. 2001; Galasko et al. 1998; 
Hulstaert et al. 1999; Riemenschneider et al. 1996). 
However, total tau and Aβ42 have also been found 
at similar levels in the CSF of other dementias 
(Blennow et al. 2003; Green et al. 1999; Hampel 
et al. 2003; Molina et al. 1999; Kanemaru et al. 
2000), but not in all (Blennow, 2003; Motter 
et al. 1995; Vigo-Pelfrey et al. 1995; Hulstaert et al. 
1999; Sjögren et al. 2000). Additionally, increased 
levels of total tau have been correlated to increasing 
age in non-demented subjects (Hampel et al. 2003; 
Buerger et al. 1999; Sjögren, 2001). Thus the 
presence of these proteins in CSF does not appear to 
be specific to AD and cannot provide a reliable 
diagnostic biomarker.
In addition to tau protein and Aβ peptides, recent 
studies indicate that levels of certain phosphorylated 
forms of tau increase significantly in CSF of AD 
patients (Ewers et al. 2007; Brys et al. 2007; 
Kohnken et al. 2000; Arai et al. 2000; Vanmechelen 
et al. 2000; Hampel, 2003), but not in vascular 
dementia, frontotemporal dementia (Sjögren et al. 
2000), Lewy body dementia, (Parnetti et al. 2001) 
or geriatric major depression (Buerger et al. 2003). 
Further, multiple studies have shown that when 
examining in combination the levels of phosphory-
lated tau, total tau and Aβ in cerebrospinal fluid 
(CSF), one can figure out a MCI patient’s probabil-
ity for progressing to AD (Brys et al. 2007; Diniz 
et al. 2007; Herukka et al. 2007). These studies sug-
gest that phosphorylated tau levels in CSF may be 
able to help clinically delineate AD from other forms 
of dementia (Blennow et al. 2003) to improve early 
detection and to track progression of AD.
To increase the accuracy of these proteins as a 
diagnostic, it would be interesting to combine this 
predictive set of proteins to other genetic and 
functional imaging biomarkers of AD to determine 
their combined predictive utility in a prospective 
longitudinal study of healthy controls and MCI 
patients. This may aid in the accurate early detec-
tion of AD so that therapies, which are currently 
in development, may be initiated prior to substan-
tial and possibly irreparable neuronal cell loss.
It will be important to expand this analysis to a 
larger AD sample set, as well as to determine the 
specificity of these biomarkers for AD compared 
to other neurodegenerative diseases. Aside from 
this, there are at least two important implications 
from this finding. The first is that it is unlikely that 
a single gene or protein will serve as a useful diag-
nostic for complex disorders. More reasonably, a 
set of proteins or genes will be the most useful set 
of disease predictors. Second, this example illus-
trates that accurate biomarkers can be used to track 
disease progression from early stages to more 
advanced stages, in addition to being used as a 
molecular diagnostic for end-stage disease. This 
provides the hope that complex, progressive neu-
rodegenerative disease can be pre-symptomatically 
diagnosed, thereby increasing the likelihood that 
therapeutic intervention will be successful.
Huntington’s Disease (HD) is a neurodegenera-
tive disorder for which protein biomarkers have 
been discovered to reflect pathological status. In 
one notable proteomics profiling study, 18 candi-
date proteins were found to be differentially 
expressed in human plasma at different stages of 
HD compared to non-HD control samples. Blood 
samples were taken from patients in one of five 
disease stages: control (no disease); premanifest 
(positive for HD gene mutation but absent motor 
abnormalities); early HD; moderate HD; and 
advanced HD. Samples were subjected to two 
independent 2D Gel Electrophoresis studies and 
computer-assisted silver-staining imaging with 
digital background subtraction. Significant spots 
from these first studies were then identified using 83
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MS and quantified by Immunoblotting. The most 
promising HD biomarker finding was clusterin 
(apolipoprotein J), a disulfide-linked heterodimeric 
protein found in most mammalian tissues and bio-
fluids. The presence of clusterin is associated with 
cytoprotection, membrane recycling, apoptosis, and 
response to injury (Jones and Jomary, 2002; Dal-
rymple et al. 2007). Notably, it is linked to immune 
activation, a known systemic abnormality in HD 
and other neurodegenerative disease. In this study, 
clusterin was discovered to be upregulated in the 
HD plasma samples, with levels following disease 
progression (Dalrymple et al. 2007). Overall, 
clusterin shows promise in acting as a biomarker 
of HD because it can be obtained from easily acces-
sible biofluid, it tracks linearly with HD pathology, 
and it is linked mechanistically to the pathogenesis 
of the disease. However, because clusterin has also 
been reported to be upregulated at the mRNA level 
in AD, the specificity of this protein for HD will 
need to be tested further (Dunckley et al. 2006b).
Biomarkers based on proteomic discoveries are 
advantageous in that peripheral tissues that are eas-
ily obtained in a clinic setting, such as saliva, serum, 
urine, or cerebral spinal fluid can be used for testing 
diagnostic signatures. This will provide a critical 
diagnostic adjunct to clinical disease assessment 
and will likely help to direct individuals to the most 
appropriate treatment options earlier than would 
otherwise happen if clinical assessments are used 
alone. Figure 2 summarizes the workflow for the 
use of proteomic technologies in biomarker discov-
ery for neurological diseases. These technologies, 
though advanced substantially in the last decade, 
Figure 2. Work ﬂ  ow for proteomic biomarker discovery in neurological diseases. Abbreviations used are 2DE (2-dimensional gel 
electrophoresis), LC (liquid chromatography), DIGE (2-D ﬂ  uorescence difference gel electrophoresis), ICAT (isotope-coded afﬁ  nity tag), 
iTRAQ (isobaric tagging for relative and absolute quantitation), PMF (peptide mass ﬁ  ngerprinting, MS/MS (tandem mass spectrometry).
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need to move further to expand the capacity to 
interrogate a larger number of proteins, including 
low abundance proteins and proteins undergoing 
disease relevant post-translational modifications. 
Ultimately, proteomic technologies hold significant 
promise in identification of biomarkers for disease 
diagnosis, tracking of disease progression, and 
monitoring of treatment efficacy.
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